Not all dengue patients with low platelet count need transfusions: Study
Only about 5 per cent of dengue patients face complications such as severe bleeding and thus will require transfusions. Findings from the study show that most patients with critically low platelet counts will recover by themselves after a few days.
SINGAPORE, March 30, 2017 /Channel NewsAsia/ —
Article by Chan Luo Er
Researchers from Malaysia and Singapore that took part in the Adult Dengue Platelet Study. (Photo: Chan Luo Er)
SINGAPORE: Dengue patients with critically low platelet counts do not require platelet transfusions to get better, as long they do not have other complications, a recent study found.
The Adult Dengue Platelet Study (ADEPT) involved researchers from Tan Tock Seng Hospital, the National University Hospital, Singapore General Hospital, Changi General Hospital and Malaysia’s University Malaya Medical Centre.
A typical person has a platelet count of between 150,000 and 250,000 per microlitre of blood.
About 80 to 90 per cent of patients with dengue will have levels below 100,000, while 10 to 20 per cent of patients will see critically low levels of 20,000 or less. In such cases, they are likely to be admitted to the hospital and receive platelet transfusions to prevent the possibility of internal bleeding.
Only about 5 per cent of dengue patients face complications such as severe bleeding and require transfusions. Findings from the study show that most patients with critically low platelet counts will recover by themselves after a few days. There is no difference in clinical bleeding with or without transfusion in those with a platelet count of less than 20,000 per microlitre.
Focus on supportive care
“The issue here is when the platelet count drops to a critically low level, most clinicians will feel unsafe not to do something,” said Professor Leo Yee Sin, director of the Institute of Infectious Diseases and Epidemiology at Tan Tock Seng Hospital. “In other words, most clinicians will go ahead to transfuse platelets to this group of uncomplicated patients and this study shows that it is not necessary to do so.”
A transfusion, just like any medical procedure, runs the risk of side effects like a severe allergic reaction, so researchers have said doctors should focus on supportive care.
For instance, dehydration is a key concern for dengue patients, so treatment could include fluid therapy.
Prof Leo said previous retrospective studies done in this area have sparked a shift in how doctors traditionally manage the virus. She hopes this study will further reduce hospital admissions.
A dengue patient will usually get one bag of pooled platelets during a transfusion. One bag will require contributions from four donors. Researchers hope the shift to supportive care will also free up supplies for those who need it – especially in the event of a dengue outbreak.
The World Health Organization has issued recommendations against transfusions since 2009, but Prof Leo said that until this study, there was no conclusive evidence against doing so.
The study enlisted 372 patients between 2010 and 2014 across the four public hospitals in Singapore. It was funded by the National Medical Research Council (NMRC) under STOP-Dengue Translational Clinical Research Programme and coordinated by the Singapore Clinical Research Institute (SCRI).
The study was recently accepted by Lancet medical journal.
“More of the community doctors are getting more comfortable in taking care of patients in their own clinic setting without referring them to the hospital, without referring them for admission,” said Prof Leo. “I think this trend will continue to shift the focus of dengue care into primary care and leave the more complicated cases in tertiary care.”
Researchers will next look at the cost-effectiveness of transfusions and how resources that are freed up could be used in other ways. They hope to come up with results in a year.